Apex Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Apex Capital Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,694,853	Closed	-$5.97M	–	260
2015 Q3	$5.97M	Sell	1,694,853 -519,261	-23%	-$3.48M	0.14%	134
2015 Q2	$22.1M	Buy	2,214,114 +128,420	+6%	+$1.38M	0.47%	73
2015 Q1	$26.6M	Buy	2,085,694 +241,940	+13%	+$3.11M	0.63%	64
2014 Q4	$26.1M	Buy	1,843,754 +127,784	+7%	+$1.98M	0.7%	56
2014 Q3	$23.6M	Buy	1,715,970 +596,798	+53%	+$9.14M	0.71%	58
2014 Q2	$17.2M	Buy	1,119,172 +214,859	+24%	+$3.05M	0.53%	70
2014 Q1	$15.4M	Buy	904,313 +91,912	+11%	+$1.39M	0.54%	66
2013 Q4	$10.5M	Buy	+812,401	New	+$9.7M	0.39%	76

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Apex Capital Management's KERX Position: Q4 2015 in Review

Apex Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 1,694,853 shares — an estimated $5.97M sold.

Apex Capital Management first reported a position in KERX in Q4 2013 and held it in 8 quarters. The position peaked at $26.6M in Q1 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

Apex Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
Apex Capital Management sold 1,694,853 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $5.97M.
Apex Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 8 quarters.
Apex Capital Management's Keryx Biopharmaceuticals Inc position peaked at $26.6M in Q1 2015.
128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on Apex Capital Management's 13F filing for Q4 2015, filed 20 Jan 2016.